Clinical trials: Clinical Malaria
Advanced Cancers
Plasmodium Immunotherapy for Advanced Cancers
The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of…
- Trial name
- NCT03375983
- Testing
- Blood-stage infection of P.vivax
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
Malaria
Trial to Evaluate L9LS in Healthy Adults
Background: Malaria is a parasitic disease carried by mosquitoes in tropical areas. There is no vaccine to prevent malaria infection. If not treated right away, it can become serious or deadly.
- Trial name
- VRC 614 (NCT05019729)
- Testing
- VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Malaria Transmission and Clinical Malaria
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
This is a Phase 1, individually randomized, double-blind, dose escalating study designed to evaluate the safety, tolerability, and immunogenicity of Pfs230D1 conjugate vaccines, R21 nanoparticle vaccine, or their combination…
- Trial name
- NCT06507605
- Testing
- R21, Pfs230D1-CRM197, Pfs230D1-EPA
- Where
- Mali
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Plasmodium Falciparum Malaria
Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P.
- Trial name
- NCT01594931
- Testing
- pyronaridine/artesunate
- Where
- 6 sites in Cambodia, Indonesia and 4 more
- Volunteers
- 477 people
- Sponsor
- Medicines for Malaria Venture
Malaria
Pan-Malaria Transmission-Blocking Vaccine AnAPN1
Malaria is still responsible for more than 627,000 deaths each year, predominantly among children under 5 years old. Current reductions in deaths have stagnated, and additional setbacks for malaria control programs due to the…
- Trial name
- PamTBVac (NCT05905432)
- Testing
- Vaccine AnAPN1
- Where
- Gabon
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated Plasmodium Falciparum Malaria
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Background: Artemisinin resistance has emerged in parts of Southeast Asia, and there are reports in Africa of reduced susceptibility of Plasmodium falciparum parasites against artemisinin-based combination therapy (ACT).
- Trial name
- 3ACT (NCT05764746)
- Testing
- Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine
- Where
- 2 sites in Tanzania
- Volunteers
- 384 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria
Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria?
The investigators performed a prospective study, in order to assess the feasibility and safety of restricting antimalarials to rapid diagnostic test (RDT)-confirmed cases in children aged 5 to 15 years-old
- Trial name
- NCT00913146
- Where
- Benin
- Volunteers
- 484 people
- Sponsor
- Institut de Recherche pour le Developpement
Malaria
Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania
General objective: To improve the quality of fever case management in children in government health facilities in Tanzania Hypothesis:The training of health workers, as well as provision, training and use of microscopes for…
- Trial name
- NCT00687895
- Testing
- Clinical algorithm and microscopy diagnosis of malaria
- Where
- Tanzania
- Volunteers
- 3,131 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Plasmodium Falciparum Malaria, Pregnancy Malaria
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Malaria during pregnancy remains an important public health issue in endemic countries. Most cases of malaria in pregnant women are asymptomatic, and can contribute to adverse outcomes, such as maternal and neonatal anaemia as…
- Conditions
- Plasmodium Falciparum Malaria, Pregnancy Malaria, Diagnoses Disease
- Trial name
- NCT03462615
- Testing
- HS-RDT
- Where
- Papua New Guinea
- Volunteers
- 930 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Malaria
Trial to Evaluate CIS43LS in Healthy Adults
Background: People get malaria when they are bitten by an infected mosquito. Malaria can be serious and sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that fully prevents infection.
- Trial name
- NCT04206332
- Testing
- VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum, Pregnancy Malaria
Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women
This is a cross-sectional and multicentre clinical trial to study the performance of the Histidine Rich Protein 2 (HRP2) highly sensitive rapid diagnostic test (HS-RDT) for the detection of malaria during pregnancy in low…
- Conditions
- Plasmodium Falciparum, Pregnancy Malaria, Diagnoses Disease
- Trial name
- HSRDT MiP (NCT03172221)
- Testing
- HS-RDT
- Where
- 2 sites in Colombia
- Volunteers
- 880 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Plasmodium Falciparum Malaria
Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005
The primary objective of the study was to determine the PCR-APCR up to day 42 in children <60 months of age, weighing ≥5kg with uncomplicated malaria, treated with either artesunate+ amodiaquine (ASAQ) or artemether-lumefantrine…
- Trial name
- ACOII (NCT03768908)
- Testing
- Artemether-lumefantrine, Artesunate + Amodiaquine
- Volunteers
- 359 people
- Sponsor
- Professor Anders Björkman
Vaccine Reaction
A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults
A Phase 1, open label clinical study to evaluate the safety, immunogenicity, tolerability and efficacy of Plasmodium falciparum Malaria Protein 014 (FMP014) combined with (ALF with QS-21), saponin molecule derived from the bark…
- Trial name
- NCT04296279
- Testing
- FMP014, ALFQ
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
This is a randomized, double blind, placebo-controlled, single site, trial of a condensed regimen of PfSPZ Vaccine administered on Days 1, 8 and 29 by direct venous inoculation (DVI) to assess safety, tolerability, immunogenicity…
- Trial name
- NCT04966871
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Dengue, Chikungunya
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
The differential and systematic diagnosis of malaria, dengue and chikungunya in patients with fever (≥38.5°C) of undetermined etiology would allow the identification of infection by these pathogens and thus limit the…
- Conditions
- Dengue, Chikungunya, Malaria
- Trial name
- NCT06257810
- Testing
- VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG, Standard of care practices
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire
- Volunteers
- 804 people
- Sponsor
- BioMérieux
Neurological Disorders, Cerebral Malaria
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
The impact of neurological disorders is enormous worldwide, and it is increased in poor settings, due to lack of diagnosis and treatment facilities as well as delayed management.
- Conditions
- Neurological Disorders, Cerebral Malaria, Bacterial Meningitis, Central Nervous System Tuberculosis
- Trial name
- Nidiag-Neuro (NCT01589289)
- Testing
- Immunochromatographic HAT tests (DSD), Card Agglutination Trypanosoma Test, TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)
- Where
- Democratic Republic of the Congo
- Volunteers
- 352 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria, Vivax
Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers
This is a randomized, double-blind, controlled, which seeks to compare two groups of volunteers (naive and previously exposed to malaria) vaccinated with three doses of a synthetic derivative of the CS protein of Plasmodium vivax…
- Trial name
- NCT04739917
- Testing
- Vaccine PvCS N+C+R 150 mcg
- Where
- Colombia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet
The primary objective of this study is to determine the bioequivalence of the combination of pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference tablet administered as a single total dose…
- Trial name
- NCT00682630
- Testing
- pyronaridine artesunate clinical trial reference tablets, pyronaridine artesunate to-be-marketed tablets
- Where
- Switzerland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria
This is a bi-centric phase IIIb, randomized, open label, 3-arm clinical trial performed to investigate the impact of retreatment with an Artemisinin-Based Combination (ACT), for example Arthemeter-Lumefantrine (AL) in Uganda (Ug)…
- Trial name
- QuinAct (NCT01374581)
- Testing
- Artemether/Lumefantrine, Artesunate/Amodiaquine, Quinine + Clindamycin
- Where
- 2 sites in Republic of the Congo, Uganda
- Volunteers
- 2,117 people
- Sponsor
- Universiteit Antwerpen
Malaria in Pregnancy
Follow-up of Immunological Pattern and Pregnancy Outcomes in Women Previously Received Placental Malaria Vaccine
Study Population: Participants of the previous PRIMVAC vaccine trial and women aged 18 to 35 years Sample Size: 90 Study duration: 21 months Subject duration: 12 months if pregnancy doesn't occurred.
- Trial name
- PRIMVACLongT (NCT05426187)
- Where
- Burkina Faso
- Volunteers
- 90 people
- Sponsor
- Groupe de Recherche Action en Sante